Randomised, Double-Blind, Double-Dummy, Parallel-Group Multicentre Study to Demonstrate Non-Inferiority in Pain and Locomotor Function and Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee and/or Hip Taking Oxycodone Equivalent of 20 - 80 mg/Day as Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Subjects Taking Oxycodone Prolonged Release Tablets (OxyPR) Alone.

Trial Profile

Randomised, Double-Blind, Double-Dummy, Parallel-Group Multicentre Study to Demonstrate Non-Inferiority in Pain and Locomotor Function and Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee and/or Hip Taking Oxycodone Equivalent of 20 - 80 mg/Day as Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Subjects Taking Oxycodone Prolonged Release Tablets (OxyPR) Alone.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2012

At a glance

  • Drugs Oxycodone/naloxone (Primary) ; Oxycodone
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 28 Apr 2012 Additional trial locations (Netherlands, Austria) identified as reported by European Clinical Trials Database.
    • 28 Apr 2012 Planned number of patients changed from 200 to 260 as reported by European Clinical Trials Database.
    • 16 Feb 2012 Actual patient number is 181 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top